Kidney Cancer Journal 47
renal cell carcinoma (mRCC). Results from the International Metastatic
Renal Cell Carcinoma Database Consortium (IMDC). Kidney Cancer.
2018;2:31-36.
13. Davis ID, Xie W, Pezaro C, et al. Efficacy of Second-line Targeted
Therapy for Renal Cell Carcinoma According to Change from Baseline
in International Metastatic Renal Cell Carcinoma Database Consortium
Prognostic Category. Eur Urol. 2017;71:970-978.
14. Motzer RJ, Bacik J, Schwartz LH, Reuter V, Russo P, Marion S et al
(2004) Prognostic factors for survival in previously treated patients with
metastatic renal cell carcinoma. J Clin Oncol. 22(3):454–463
15. Ko JJ, Xie W, Kroeger N, et al. The International Metastatic Renal
Cell Carcinoma Database Consortium model as a prognostic tool in patients
with metastatic renal cell carcinoma previously treated with firstline
targeted therapy: a population-based study. Lancet Oncol. 2015;
16:293-300
16. Albiges L., Negrier S., Dalban C. et al. Safety and efficacy of nivolumab
in metastatic renal cell carcinoma Final analysis from the NIVOREN
GETUG AFU 26 study. J Clin Oncol. 37, 2019, suppl 7S; abstr 542.
17. Derosa L Bayar MA, Albiges L et al. A new prognostic model for survival
in second line for metastatic renal cell carcinoma: development
and external validation. Angiogenesis. 2019 Feb 9.
18. Wells JC, Stukalin I, Norton C, et al. Third-line targeted therapy in
metastatic renal cell carcinoma: Results from the International Metastatic
Renal Cell Carcinoma Database Consortium. Eur Urol. 2017;71:
204-209.
19, Graham J, Dudani S, Heng DYC. Prognostication in kidney cancer:
recent advances and future directions. J Clin Oncol. 2018;Oct 29:
JCO20189014.
20. Tannir NM, Frontera OA, Hammers HJ et al. Thirty-month followup
of the phase III CheckMate 214 trial of first-line nivolumab + ipilimumab
(N+I) or sunitinib (S) in patients (pts) with advanced renal cell
carcinoma (aRCC). J Clin Oncol. 37, 2019 (suppl 7S; abstr 547)
21. Lee CK, Man J, Lord S et al. Checkpoint Inhibitors in Metastatic
EGFR-Mutated Non-Small Cell Lung Cancer-A Meta-Analysis. J Thorac
Oncol. 2017 Feb;12(2):403-407.
22. Carlo MI, Manley B, Patil S, et al. Genomic alterations and outcomes
with VEGF-targeted therapy in patients with clear cell renal cell carcinoma.
Kidney Cancer. 2017;1:49-566.
23. Turajlic S, Xu H, Litchfield K et al. Deterministic Evolutionary Trajectories
Influence Primary Tumor Growth: TRACERx Renal. Cell. 2018
Apr 19;173(3):595-610.e11.
24. Voss MH, Cheng Y, Marker M, et al. In corporation of PBRM1, BAP1,
TP53 mutation status into the Memorial Sloan Kettering Cancer Center
(MSKCC) risk model: A genomically annotated tool to improve stratification
of patients (pts) with advanced renal cell carcinoma (RCC). J Clin
Oncol. 36:639, 2018
25. Bosse D, Xie W, Lalani A-KA, et al. Genomic alterations to refine
prognostication of patients with metastatic renal cell carcinoma. J Clin
Oncol. 36:626, 2018
26. De Velasco G, Culhane A, Fay AP et al. Molecular Subtypes Improve
Prognostic Value of International Metastatic Renal Cell Carcinoma Database
Consortium Prognostic Model. Oncologist. 2017 Mar;22(3):286-
292.
27. Beuselinck B, Job S, Becht E, et al. Molecular subtypes of clear cell
carcinoma are associated with sunitinib response in the metastatic setting.
Clin Cancer Res. 2015;21:1329-1339.
28. Beuselinck B, Verbiest A, Couchy G, et al. Tumor molecular characteristics
in patients (pts) with international metastatic renal cell carcinoma
database consortium (IMDC) good (G) and intermediate/poor
(I/P) risk. Ann Oncol. 2018;29:suppl, 1 October mdy283.078
29. Ueda K, Suekane S, Kurose H et al. Prognostic value of PD-1 and PDL1
expression in patients with metastatic clear cell renal cell carcinoma.
Urol Oncol. 2018 Nov;36(11):499.e9-499.e16.
30. Higenell V., Fajzel R., Batist G. et a. A network approach to developing
immuno-oncology combinations in Canada. Curr Oncol. 2019 Apr;
26(2). KCJ
changes to the format or focus of the International Symposium.
These symposia allow us to have a ‘meeting of
the minds’ between clinicians, pharma, scientists, and researchers.
By collaborating on the highest level, we are
able to share valuable findings and create a great sense of
hope for the future. Through teamwork with clinical trials,
new drugs, and new research, these symposia are essential
in distributing information and determining
future endeavors.
Q: Do you have any plans to revamp the KCA website,
perhaps to create a more interactive focus for physicians?
Blogs, etc?
Ms Vaughan: Updating the website to be more userfriendly
is a large part of the conversation as we develop
our multi-year strategic plan. For physicians and researchers,
we want to serve as a resource hub to support
them in their efforts to bring an end to death and suffering
from renal cancers. For patients, we want to provide
easy navigation to the resources available, including the
helpline staffed by a dedicated team of nurses, detailed
information on understanding and locating clinical trials,
and access to the Inspire support platform. Our primary
goal is to provide patients, their families, and their caretakers
with the information and resources they need in
the most efficient and effective way possible. Generally
speaking, we expect to refresh the website with new opportunities,
content, and information as identified in the
strategic planning process. KCJ
(Interview, continued from page 34)